IL310432A - Antibodies and antibody conjugates specific for nectin-4 and methods of using them - Google Patents

Antibodies and antibody conjugates specific for nectin-4 and methods of using them

Info

Publication number
IL310432A
IL310432A IL310432A IL31043224A IL310432A IL 310432 A IL310432 A IL 310432A IL 310432 A IL310432 A IL 310432A IL 31043224 A IL31043224 A IL 31043224A IL 310432 A IL310432 A IL 310432A
Authority
IL
Israel
Prior art keywords
nectin
antibodies
methods
antibody conjugates
conjugates specific
Prior art date
Application number
IL310432A
Other languages
English (en)
Hebrew (he)
Inventor
Dominick Yeo
Maxine Bauzon
Fangjiu Zhang
Stepan Chuprakov
Yun C Kim
Robyn M Barfield
Penelope M Drake
Original Assignee
Scherer Technologies Llc R P
Dominick Yeo
Maxine Bauzon
Fangjiu Zhang
Stepan Chuprakov
Yun C Kim
Robyn M Barfield
Penelope M Drake
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scherer Technologies Llc R P, Dominick Yeo, Maxine Bauzon, Fangjiu Zhang, Stepan Chuprakov, Yun C Kim, Robyn M Barfield, Penelope M Drake filed Critical Scherer Technologies Llc R P
Publication of IL310432A publication Critical patent/IL310432A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL310432A 2021-07-30 2022-07-28 Antibodies and antibody conjugates specific for nectin-4 and methods of using them IL310432A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163227666P 2021-07-30 2021-07-30
US202263322914P 2022-03-23 2022-03-23
US202263344932P 2022-05-23 2022-05-23
PCT/US2022/038720 WO2023009751A2 (en) 2021-07-30 2022-07-28 Antibodies and antibody conjugates specific for nectin-4 and methods of use thereof

Publications (1)

Publication Number Publication Date
IL310432A true IL310432A (en) 2024-03-01

Family

ID=85088249

Family Applications (1)

Application Number Title Priority Date Filing Date
IL310432A IL310432A (en) 2021-07-30 2022-07-28 Antibodies and antibody conjugates specific for nectin-4 and methods of using them

Country Status (8)

Country Link
EP (2) EP4377320A2 (ko)
JP (2) JP2024529506A (ko)
KR (2) KR20240049858A (ko)
AU (2) AU2022319782A1 (ko)
CA (2) CA3227844A1 (ko)
IL (1) IL310432A (ko)
MX (2) MX2024001396A (ko)
WO (3) WO2023009751A2 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024529506A (ja) * 2021-07-30 2024-08-06 アール．ピー．シェーラー テクノロジーズ，エルエルシー ネクチン－４に特異的な抗体および抗体複合体、並びにそれらの使用方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2770399T3 (es) * 2012-09-19 2020-07-01 Innate Pharma Agentes de unión a KIR3DL2
US9310374B2 (en) * 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
JP6745218B2 (ja) * 2013-11-27 2020-08-26 レッドウッド バイオサイエンス， インコーポレイテッド ヒドラジニル−ピロロ化合物及び複合体を生成するための方法
KR20180102065A (ko) * 2015-11-09 2018-09-14 알.피.쉐러 테크놀러지즈 엘엘씨 항-cd22 항체-메이탄신 콘쥬게이트 및 그것의 사용 방법
KR102127421B1 (ko) * 2017-03-21 2020-06-26 주식회사 펩트론 Muc1에 특이적으로 결합하는 항체 및 그의 용도
WO2019113248A1 (en) * 2017-12-07 2019-06-13 The Regents Of The University Of California Anti-upar antibody-drug conjugates and methods of use thereof
SG11202004579RA (en) * 2017-12-11 2020-07-29 Triphase Res And Development Iii Corp Anti-cd22 antibody-maytansine conjugates, combinations, and methods of use thereof
MX2020007555A (es) * 2018-01-15 2021-01-15 Stichting Sanquin Bloedvoorziening Anticuerpos potenciadores del factor h y usos de los mismos.
CN112088167A (zh) * 2018-05-09 2020-12-15 耶路撒冷希伯来大学伊森姆研究发展有限公司 特异性针对人类连接蛋白4的抗体
CA3127098A1 (en) * 2019-01-23 2020-07-30 R.P. Scherer Technologies, Llc Glycoside-containing peptide linkers for antibody-drug conjugates
JP2024529506A (ja) * 2021-07-30 2024-08-06 アール．ピー．シェーラー テクノロジーズ，エルエルシー ネクチン－４に特異的な抗体および抗体複合体、並びにそれらの使用方法

Also Published As

Publication number Publication date
EP4377320A2 (en) 2024-06-05
JP2024529466A (ja) 2024-08-06
KR20240040098A (ko) 2024-03-27
WO2023009835A3 (en) 2023-10-26
WO2023009759A3 (en) 2023-04-13
JP2024529506A (ja) 2024-08-06
AU2022319782A1 (en) 2024-02-15
KR20240049858A (ko) 2024-04-17
CA3227845A1 (en) 2023-02-02
EP4377319A2 (en) 2024-06-05
WO2023009751A3 (en) 2023-03-09
WO2023009759A2 (en) 2023-02-02
WO2023009835A9 (en) 2024-01-04
WO2023009751A2 (en) 2023-02-02
CA3227844A1 (en) 2023-02-02
AU2022320714A1 (en) 2024-02-08
WO2023009835A2 (en) 2023-02-02
MX2024001396A (es) 2024-05-09
MX2024001301A (es) 2024-04-18

Similar Documents

Publication Publication Date Title
GB202019709D0 (en) Anti-Coronavirus antibodies and methods of use
EP4010378A4 (en) ANTICCR8 MONOCLONAL ANTIBODIES AND USES THEREOF
NO20071436L (no) Humaniserte Anti-5T4 antistoffer og Anti-5T4 antistoff/calicheamicin konjugater
SI3972987T1 (sl) Antigen-specifična imunoterapija za covid-19 fuzijske proteine in postopki za uporabo
EP4148068A4 (en) ANTI-TIGIT ANTIBODY, PREPARATION METHOD AND USE THEREOF
EP3915581A4 (en) NOVEL CANCER ANTIGENS AND ANTIBODIES OF THESE ANTIGENS
EP4201958A4 (en) ANTI-CTLA-4 ANTIBODY AND ITS USE
EP3981793A4 (en) CEACAM5-RESISTANT MONOCLONAL ANTIBODY AND METHODS FOR ITS PRODUCTION AND ITS USE
IL304332A (en) lrrc15 antibodies and their conjugates
IL310432A (en) Antibodies and antibody conjugates specific for nectin-4 and methods of using them
EP4061847A4 (en) ANTI-B7-H3 MONOCLONAL ANTIBODY AND METHODS OF USE THEREOF
EP4095155A4 (en) METHOD FOR IMPROVING THE AFFINITY OF AN ANTIBODY AGAINST AN ANTIGEN AND USE THEREOF
EP4093884A4 (en) METHODS FOR IDENTIFYING LIGAND-BLOCKING ANTIBODIES AND DETERMINING ANTIBODY POWER
IL278225A (en) Anti SEZ6 antibody drug conjugates and methods of use
IL308260A (en) Antibodies against Tigit and methods of using them
EP4126046A4 (en) ANTI-GIPR ANTIBODIES AND METHODS OF USE THEREOF
IL306129A (en) Structures of antigen-binding proteins and antibodies and their uses
EP4274851A4 (en) MONOCLONAL ANTI-GPRC5D ANTIBODIES AND USES THEREOF
IL300104A (en) Antibody specific for mucin-1 and methods of using it
EP4339208A4 (en) ANTI-TIGIT ANTIBODIES AND THEIR USE
IL310551A (en) Monoclonal antibodies specific for OSMR and methods of using them
GB202106075D0 (en) Monoclonal antibodies for cancer immunotherapy and methods of use thereof
EP4142778A4 (en) ANTI-CD79B ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF
IL311003A (en) Anti-2HER antibodies and methods of using them
IL311301A (en) Anti-SIGLEC-6 antibodies and methods of using them